1 Tashkent State Medical University, Department of Hematology, Transfusiology and Laboratory Medicine
2 Tashkent State Medical University
ReceivedJul 10, 2026
RevisedJul 25, 2026
PublishedJul 30, 2026
Annotatsiya
Rheumatoid arthritis is frequently accompanied by platelet activation, coagulation imbalance, and endothelial dysfunction, which may persist despite standard anti-inflammatory treatment. This study evaluated the effects of standard therapy and pathogenetically oriented combined therapy on platelet function, coagulation parameters, and endothelial dysfunction markers in patients with rheumatoid arthritis. Patients without adverse thrombophilia-related genotypes received either standard treatment alone or standard treatment supplemented with endothelial, antiplatelet, and anticoagulant correction, whereas patients with adverse genotypes received genotype-oriented therapy that additionally included folate correction. Platelet count, adhesion, aggregation, activated partial thromboplastin time, prothrombin index, fibrinogen, D-dimer, endothelin-1, and soluble intercellular adhesion molecule were assessed before and after treatment. Platelet count decreased after therapy but did not normalize consistently. In contrast, platelet adhesion and aggregation improved more markedly with combined therapy than with standard treatment. Among patients without adverse genotypes, adhesion decreased from 46–52 to 28–30, while aggregation decreased from 49–52 to 31–33. Activated partial thromboplastin time increased from 19.5–24.2 seconds to 30.5–38.5 seconds, fibrinogen decreased from 3.55–4.66 g/L to 2.44–3.13 g/L, and D-dimer declined from 380–460 ng/mL to 291–332 ng/mL. Endothelin-1 and soluble intercellular adhesion molecule levels also decreased more substantially after combined therapy. These findings indicate that pathogenetically oriented combined treatment provides more pronounced correction of platelet hyperactivity, hypercoagulability, and endothelial dysfunction than standard therapy alone.
1. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. https://doi.org/10.1136/ard-2022-223356.
2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-1588. https://doi.org/10.1136/ard.2010.138461.
3. Yang XZ, Chang Y, Wei W. Endothelial dysfunction and inflammation: immunity in rheumatoid arthritis. Mediators Inflamm. 2016;2016:6813016. https://doi.org/10.1155/2016/6813016.
4. Adamantidi T, Pisioti MS, Pitsouni S, Chatzikamari M, Karamanis G, Dania V, et al. The inflammatory link of rheumatoid arthritis and thrombosis: pathogenic molecular circuits and treatment approaches. Curr Issues Mol Biol. 2025;47(4):291. https://doi.org/10.3390/cimb47040291.
5. Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis. 2021;80(2):169-175. https://doi.org/10.1136/annrheumdis-2020-218419.
6. Hu LJ, Ji B, Fan HX. Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(22):7005-7013. https://doi.org/10.26355/eurrev_202111_27249.
7. Manz XD, Doddaballapur A, Hynes RO, Wagner DD. Regulation of VWF (von Willebrand factor) in inflammatory thrombosis. Arterioscler Thromb Vasc Biol. 2022;42(11):1307-1320. https://doi.org/10.1161/ATVBAHA.122.318179.
8. Bagheri-Hosseinabadi Z, Imani D, Yousefi H, Abbasifard M. MTHFR gene polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis based on 16 studies. Clin Rheumatol. 2020;39(8):2267-2279. https://doi.org/10.1007/s10067-020-05031-5.
9. Głuszek J, Wierzowiecka M, Niklas K, Niklas A. The importance of homocysteine in the development of cardiovascular complications in patients with rheumatoid arthritis. Reumatologia. 2020;58(5):282-288. https://doi.org/10.5114/reum.2020.99732.
10. Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Rodriguez L, Miranda-Filloy JA, Fernandez-Gutierrez B, et al. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther. 2010;12(2):R71. https://doi.org/10.1186/ar2989.
11. Fujimaki C, Hayashi H, Tsuboi S, Matsuyama T, Kosuge K, Yamada H, et al. Plasma total homocysteine level and methylenetetrahydrofolate reductase 677C>T genetic polymorphism in Japanese patients with rheumatoid arthritis. Biomarkers. 2009;14(1):49-54. https://doi.org/10.1080/13547500902730664.
12. Yxfeldt A, Wållberg-Jonsson S, Hultdin J, Rantapää-Dahlqvist S. Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-vitamin treatment. Scand J Rheumatol. 2003;32(4):205-210. https://doi.org/10.1080/03009740310003686.
13. van Ede AE, Laan RFJM, Blom HJ, Boers GHJ, Haagsma CJ, Thomas CMG, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41(6):658-665. https://doi.org/10.1093/rheumatology/41.6.658.
14. Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014;41(6):1049-1060. https://doi.org/10.3899/jrheum.130738.
15. Vona R, Di Franco M, Gambardella L, Di Lollo AC, Iannuccelli C, Valesini G, et al. Potential role of platelets for atherosclerotic events in rheumatoid arthritis. FEBS Open Bio. 2018;8(12):1888-1896. https://doi.org/10.1002/2211-5463.12531.
Maqolaga iqtibos keltirish andozasi
Musaeva N, Babadjanova Sh (2026). PATHOGENETICALLY ORIENTED CORRECTION OF PLATELET ACTIVITY, COAGULATION IMBALANCE AND ENDOTHELIAL DYSFUNCTION IN RHEUMATOID ARTHRITIS. Science and Innovation, 5(7), 38-46. https://doi.org/10.67620/sai.57d0005